ArticleYonago acta medica2025
Burn Injury-Induced HMGB1 Release Leads to Lung Damage Through Pulmonary Intercellular Barrier Disruption.
Article in Yonago acta medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Infections in Burn Patients: Pathophysiology, Prevention, and Contemporary Therapeutic Strategies in the Era of Antimicrobial Resistance.Infectious diseases and therapy · 2026Review
- Endocrine disruptions in thermal injuries: exploring immune system interactions.Physiological reviews · 2026Review
- Mitochondria as a Therapeutic Target for Burn Injury.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extensive burns induce systemic inflammation and increase vascular permeability, resulting in dehydration and edema. During burn injury, the release of high-mobility group box 1 (HMGB1) from damaged cells may promote an inflammatory response. In this study, we examined the relationship between changes in blood HMGB1 levels, vascular permeability, and lung tissue damage following burn injury. Methods: We examined changes in blood levels of HMGB1 using a mouse model of skin burns. Additionally, we examined intercellular adhesion structures that regulate the barrier function both the skin and lung. To assess changes in vascular permeability, lung tissues of mice with burn injuries were stained with Evans blue. To elucidate the role of HMGB1 in mediating the observed changes, cultured human vascular endothelial cells (HUVECs) and alveolar epithelial cells (H441) were treated with mouse burn serum or HMGB1 protein. Results: Herein, we observed HMGB1 leakage from burned mouse skin and elevated blood levels of HMGB1. Vascular permeability experiments using Evans blue staining confirmed increased permeability in the lung tissues of mice with burn injuries. Measurement of transendothelial electrical resistance revealed enhanced vascular permeability and reduced expression of the intercellular junction proteins in HUVECs. Conversely, treatment of H441 cells with HMGB1 disrupted the location and expression of the tight junction protein, zonula occludens-1. Treatment with the anti-HMGB1 antibody suppressed the disruption of cell-cell junctions in HMGB1-treated cells. These altered adhesion structures were also detected in pulmonary cells of mice with burn injuries. In H441 cells, HMGB1 treatment increased the activation of atypical protein kinase C (aPKC), which is essential for the formation of epithelial-specific cell-cell junctional structures. Inhibition of aPKC suppressed HMGB1-induced disruption of intercellular junction structures. Conclusion: Collectively, these findings suggest that HMGB1-mediated dysregulation of aPKC activity may underlie burn injury-induced vascular hyperpermeability by disrupting cell-cell adhesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.